David A. Siegel Salarius Pharmaceuticals, Inc. Transaction History

Two Sigma Advisers, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.17 - $0.25 $2,754 - $4,050	-16,200 Reduced 4.97%	310,000 $60,000
Q2 2022 Aug 15, 2022	SELL	$0.16 - $0.42 $4,464 - $11,718	-27,900 Reduced 7.88%	326,200 $69,000
Q1 2022 May 16, 2022	SELL	$0.34 - $0.54 $33,257 - $52,821	-97,817 Reduced 21.64%	354,100 $141,000
Q4 2021 Feb 14, 2022	BUY	$0.49 - $1.01 $166,902 - $344,023	340,617 Added 306.04%	451,917 $224,000
Q3 2021 Nov 15, 2021	BUY	$0.8 - $1.15 $89,040 - $127,994	111,300 New	111,300 $114,000

Ticker SLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,244,650
Market Cap $5.1M
Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.